Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	30.37B
Revenue (ttm)	12.60B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.46
PE Ratio	13.55
Forward PE	12.99
Dividend	1.48 (5.69%)
Ex-Dividend Date	Jun 13, 2025

Volume	68,200
Average Volume	938,377
Open	26.20
Previous Close	26.20
Day's Range	26.20 - 26.40
52-Week Range	23.10 - 34.00
Beta	0.41
RSI	49.93
Earnings Date	Apr 28, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY